Corbus Pharma's lenabasum flunks mid-stage cystic fibrosis study

• Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) slumps 30% premarket in reaction to the announcement of topline results from 28-week Phase 2b study of lenabasum in patients with cystic fibrosis (CF).
• The study enrolled patients at high risk for recurrent pulmonary exacerbations (PEx). Subjects received lenabasum or placebo added to their background treatments for CF.
• The CF-002 Phase 2b trial did not meet the primary endpoint of a statistically significant reduction in rate of new PEx per subject per 28 weeks. Lenabasum treatment had a favorable safety profile and was well-tolerated.
• The topline data will be presented at the upcoming virtual North American Cystic Fibrosis Conference, taking place October 7-23, 2020.

https://seekingalpha.com/news/3620061-corbus-pharmas-lenabasum-flunks-mid-stage-cystic-fibrosis-study-shares-down-30